Hyperphosphatemia: Its Consequences and Treatment in Patients With Chronic Renal Disease

American Journal of Kidney Diseases

Volumn 19, Issue 4, 1992, Pages 303-317

  Delmez, James A ^a   Slatopolsky, Eduardo ^a  

^a BARNES JEWISH HOSPITAL   (United States)

Author keywords

diet; parathyroid hormone; Phosphorus; renal failure

Indexed keywords

CALCITRIOL; CALCIUM ACETATE; CALCIUM CARBONATE; CITRATE CALCIUM; MAGNESIUM; PARATHYROID HORMONE; PHOSPHORUS;

CHRONIC KIDNEY FAILURE; DIET; HEMODIALYSIS; HUMAN; HYPERPARATHYROIDISM; HYPERPHOSPHATEMIA; REVIEW;

EID: 0026607973     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-6386(12)80446-X     Document Type: Article

References (122)

1. Effect of parathyroid hormone on myocardial energy metabolism in the rat
2. Effect of parathyroid hormone on rat heart cells
3. Fatty acid oxidation in the myocardium: Effects of parathyroid hormone and CRF
4. Chronic renal failure, parathyroid hormone and fatty acids oxidation in skeletal muscle
5. Verapamil reverses PTH- or CRF-induced abnormal fatty acids oxidation in muscle
6. Effect of parathyroid hormone on energy metabolism of skeletal muscle
7. Abnormal norepinephrine uptake and release in brain synaptosomes in chronic renal failure
8. Role of parathyroid hormone in the glucose intolerance of chronic renal failure
9. Insulin release from pancreatic islets:Effects of CRF and excess PTH
10. Effect of parathyroid hormone on erythropoiesis
11. Effect of parathyroid hormone on osmotic fragility of human erythrocytes
12. Calcific cardiomyopathy in advanced renal failure
13. Myocardial calcification and cardiac dysfunction in chronic renal failure
14. Calciphylaxis in man
15. Disordered calcium and phosphorus metabolism during maintenance hemodialysis
16. Soft tissue calcification in pediatric patients with end-stage renal disease
17. Phosphate excess and progressive renal failure:The precipitation-calcification hypothesis
18. Chemical composition of the body
19. Absorption of calcium, phosphorus and magnesium
20. Oral intake of phosphorus can determine the serum concentrations of 1,25-dihydroxyvitamin D by determining its production rate in humans
21. Stimulation of 25-hydroxyvitamin D31-alpha-hydroxylase by phosphate depletion
22. Dietary phosphate deprivation in women and men: Effects on mineral and acid balances, parathyroid hormone and the metabolism of 25-OH-vitamin D
23. The role of phosphate in the secretion of parathyroid hormone in man
24. Bone and soft tissue changes with oral phosphate supplements
25. Long-term effects of high phosphate intake on parathyroid hormone levels and bone metabolism
26. On the pathogenesis of hyperparathyroidism in chronic experimental renal insufficiency in the dog
27. The role of phosphate restriction in the prevention of secondary hyperparathyroidism in chronic renal disease
28. The pathogenesis of secondary hyperparathyroidism in early renal failure
29. Determinations of serum 1,25(OH)2D levels in renal disease
30. Calcium metabolism in early chronic renal failure: Implications for the pathogenesis of hyperparathyroidism
31. Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure
32. Study of intestinal absorption of calcium in patients with renal failure
33. Intestinal absorption of calcium and whole-body calcium retention in incipient and advanced renal failure
34. Bone histology in incipient and advanced renal failure
35. Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency
36. On the mechanism of secondary hyperparathyroidism in moderate renal insufficiency
37. Relationship between serum vitamin D metabolites and dietary intake of phosphate in patients with early renal failure
38. Regulation by vitamin D metabolites of messenger RNA for pre-proparathyroid hormone in isolated bovine parathyroid cells
39. Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo by the rat
40. 1,25-dihydroxyvitamin D3 suppresses parathyroid hormone secretion from parathyroid cells in tissue culture
41. Suppression by 1,25(OH)2D3 of transcription of the parathyroid hormone gene
42. Decrease in serum immunoreactive parathyroid hormone in rats and in parathyroid hormone secretion in vitro by 1,25-dihydroxycholecalciferol
43. 1,25-dihydroxycholecalciferol and parathyroid hormone in advanced chronic renal failure: Effects of simultaneous protein and phosphorus restriction
44. How important is phosphate in the pathogenesis of renal osteodystrophy?
45. Soft tissue calcification in uremia
46. Phosphorus restriction reverses hyperparathyroidism in uremia independent of changes in calcium and calcitriol
47. Hypocalcemia may not be essential for the development of secondary hyperparathyroidism in chronic renal failure
48. Etiology of hyperparathyroidism and bone disease during chronic hemodialysis
49. The predictability of the histological features of uremic bone disease by non-invasive techniques
50. Metabolic studies of low protein diets in uremia: Calcium, phosphorus and magnesium
51. Effects of dietary protein and phosphorus restriction on the progression of early renal failure
52. Reversal of hyperparathyroidism in severe uremics following very lowprotein and low-phosphorus diet
53. The short-term effects of a low protein diet in stable renal transplant recipients
54. Effect of energy intake on nitrogen metabolism in nondialyzed patients in chronic renal failure
55. A mechanistic analysis of the National Cooperative Dialysis Study (NCDS)
56. Assessing the adequacy of dialysis
57. Metabolic balance studies and dietary protein requirements in patients undergoing continuous ambulatory peritoneal dialysis
58. Calcium and phosphorus fluxes during hemodialsis with low calcium dialysate
59. High-flux hemodiafiltration: Under six hours/week treatment
60. Improved phosphate clearances with polycarbonate membranes
61. Performance characteristics of the hemoflow F60 in high-flux hemodialfiltration
62. Phosphate removal during hemodialysis, hemodiafiltration, and hemofiltration A reappraisal
63. Studies of inorganic phosphate removal during acetate and bicarbonate dialysis
64. Effect of hematocrit on solute removal during high efficiency hemodialysis
65. Minerals, vitamin D and parathyroid hormone in continuous ambulatory peritoneal dialysis
66. The effect of aluminum hydroxide on calcium, phosphorus and aluminum balances, the serum parathyroid hormone concentrations and the aluminum content of bone in patients with chronic renal failure
67. Aluminum toxicity during regular haemodialysis
68. Fracturing dialysis osteodystrophy and dialysis encephalopathy
69. Comparison of the domestic water supply and the incidence of fractures and encephalopathy in patients on home dialysis
70. Aluminum metabolism
71. Does strict phosphorus control potentiate renal osteomalacia?
72. Effect of parathyroidectomy on bone aluminum accumulation in chronic renal failure
73. Residual renal function in hemodialysis patients may protect against hyperaluminemia
74. Clinical and laboratory features of aluminum-related bone disease
75. Early deposition of aluminum in bone in diabetic patients on hemodialysis
76. Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease
77. The effect of a high intake of calcium carbonate in normal subjects and patients with chronic renal failure
78. Chronic calcium carbonate therapy in uremia
79. The influence of a high calcium carbonate intake on bone disease in patients undergoing hemodialysis
80. Substitution of aluminum hydroxide by high doses of calcium carbonate in patients on chronic haemodialysis: Disappearance of hyperaluminaemia and equal control of hyperparathyroidism
81. Oral calcium carbonate as a phosphate-binding agent in children on dialysis: Effect on plasma aluminum levels
82. The use of calcium carbonate to treat the hyperphosphataemia of chronic renal failure
83. Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis
84. Long term effects of calcium carbonate and 2.5 mEq/L calcium dialysate on mineral metabolism
85. Calcium carbonate is an effective phosphate-binder when dialysate calcium concentration is adjusted to control hypercalcemia
86. High-dose calcium carbonate with stepwise reduction in dialysate calcium concentration: Effective phosphate control and aluminum avoidance in haemodialysis patients
87. Etiology of hypercalcemia in hemodialysis patients on calcium carbonate therapy
88. Clinical application of low calcium peritoneal dialysis
89. Role of vitamin D-dependent and vitamin D-independent mechanisms in absorption of food calcium
90. Prevention of osteitis fibrosa, aluminum bone disease and soft-tissue calcification in dialysis patients: A long-term comparison of moderate doses of oral calcium +/- Mg(OH)2 vs Al(OH)3 +/- 1 alph vitamin D3
91. Reduction of dietary phosphorus absorption by phosphorus binders A theoretical, in vitro, and in vivo study
92. Calcium acetate, an effective phosphorus binder in patients with renal failure
93. Calcium acetate control of serum phosphorus in hemodialysis patients
94. Long-term administration of calcium acetate efficiently controls severe hyperphosphataemia in haemodialysis patients
95. The treatment of uraemic hyperphosphataemia with calcium acetate and calcium carbonate: A comparative study
96. Shortterm comparison of calcium carbonate (CaCO3) and calcium acetate (CaAc) in hemodialysis patients (HDP) treated with 2.5 mEq/L calcium (Ca) dialysate
97. Calcium citrate, a nonaluminum-containing phosphate-binding agent for treatment of CRF
98. Calcium citrate markedly enhances aluminum absorption from aluminum hydroxide
99. Influence of calcium acetate or calcium citrate on intestinal aluminum absorption
100. Site and mechanism of enhanced gastrointestinal absorption of aluminum by citrate
101. The beneficial effect of ketoacids on the serum phosphate and parathyroid hormone in patients with chronic uremia
102. In vitro and in vivo studies with a non-aluminum phosphate-binding compound
103. Calcium alginate, an aluminum-free phosphate binder, in patients on CAPD
104. Intestinal absorption of mangesium from food and supplements
105. Substitution of aluminum salts by magnesium salts in control of dialysis hyperphosphataemia
106. Effects of a magnesium-free dialysate on magnesium metabolism during continuous ambulatory peritoneal dialysis
107. Long-term use of magnesium hydroxide as a phosphate binder in patients on hemodialysis
108. The use of magnesium-containing phosphate binders in patients with endstage renal disease on maintenance hemodialysis
109. Magnesium hydroxide as a complementary aluminum-free phosphate binder to moderate doses of oral calcium in uraemic patients on chronic haemodialysis
110. Treatment compliance in end-stage renal disease patients on dialysis
111. Effect of the time of administration of calcium acetate on phosphorus binding
112. Variable efficacy of calcium carbonate tablets
113. Nutritional and pharmaceutical aspects of calcium supplementation
114. Calcium bioavailability from two calcium carbonate preparations
115. Parathyroid hormone suppression by intravenous 1, 25-dihydroxyvitamin. A role for increased sensitivity to calcium
116. Direct inhibitory effect of calcitriol on parathyroid function (sigmoidal curve) in dialysis
117. 1,25(OH)2 vitamin D3 inhibits parathyroid cell proliferation in experimental uremia
118. The non-calcemic analog of vitamin D, 22-oxacalcitriol (OCT) suppresses parathyroid hormone synthesis and secretion
119. Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities
120. Assessment of nutritional status of the National Cooperative Dialysis Study population
121. A hypothesis: The protein catabolic rate is dependent upon the type and amount of treatment in dialyzed uremic patients